Tomasz (Tom) Beer

Professor

  • 15774 Citations
  • 56 h-Index
1976 …2020

Research output per year

If you made any changes in Pure these will be visible here soon.

Research Output

Filter
Article
2020

A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone

Graff, J. N., Beer, T. M., Alumkal, J. J., Slottke, R. E., Redmond, W. L., Thomas, G. V., Thompson, R. F., Wood, M. A., Koguchi, Y., Chen, Y., Latour, E., Bergan, R. C., Drake, C. G. & Moran, A. E., Jul 1 2020, In : Journal for immunotherapy of cancer. 8, 2

Research output: Contribution to journalArticle

Open Access

Association between New Unconfirmed Bone Lesions and Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide: Secondary Analysis of the PREVAIL and AFFIRM Randomized Clinical Trials

Armstrong, A. J., Al-Adhami, M., Lin, P., Parli, T., Sugg, J., Steinberg, J., Tombal, B., Sternberg, C. N., De Bono, J., Scher, H. I. & Beer, T. M., Feb 2020, In : JAMA Oncology. 6, 2, p. 217-225 9 p.

Research output: Contribution to journalArticle

Open Access
2 Scopus citations

Down-regulation of ADRB2 expression is associated with small cell neuroendocrine prostate cancer and adverse clinical outcomes in castration-resistant prostate cancer

Kwon, D. H., Zhang, L., Quigley, D. A., Foye, A., Chen, W. S., Wong, C. K., Feng, F. Y., Bailey, A., Huang, J., Stuart, J. M., Friedl, V., Weinstein, A. S., Beer, T. M., Alumkal, J., Rettig, M., Gleave, M., Lara, P. N., Thomas, G. V., Li, P., Lui, A. & 2 others, Small, E. J. & Aggarwal, R. R., 2020, (Accepted/In press) In : Urologic Oncology: Seminars and Original Investigations.

Research output: Contribution to journalArticle

Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial

Armstrong, A. J., Lin, P., Tombal, B., Saad, F., Higano, C. S., Joshua, A. M., Parli, T., Rosbrook, B., van Os, S. & Beer, T. M., 2020, (Accepted/In press) In : European Urology.

Research output: Contribution to journalArticle

1 Scopus citations

Germline polymorphisms associated with impaired survival outcomes and somatic tumor alterations in advanced prostate cancer

Chen, W. S., Feng, E. L., Aggarwal, R., Foye, A., Beer, T. M., Alumkal, J. J., Gleave, M., Chi, K. N., Reiter, R. E., Rettig, M. B., Evans, C. P., Small, E. J., Sharifi, N. & Zhao, S. G., Jun 1 2020, In : Prostate Cancer and Prostatic Diseases. 23, 2, p. 316-323 8 p.

Research output: Contribution to journalArticle

1 Scopus citations
2019

A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA)

Kapoor, R., Deek, M. P., McIntyre, R., Raman, N., Kummerlowe, M., Chen, I., Gaver, M., Wang, H., Denmeade, S., Lotan, T., Paller, C., Markowski, M., Carducci, M., Eisenberger, M., Beer, T. M., Song, D. Y., Deweese, T. L., Hearn, J. W., Greco, S., Deville, C. & 7 others, Desai, N. B., Heath, E. I., Liauw, S., Spratt, D. E., Hung, A. Y., Antonarakis, E. S. & Tran, P. T., Jun 13 2019, In : BMC cancer. 19, 1, 572.

Research output: Contribution to journalArticle

Open Access

Epigenetic therapy with panobinostat combined with bicalutamide rechallenge in castration-resistant prostate cancer

Ferrari, A. C., Alumkal, J., Stein, M. N., Taplin, M. E., Babb, J., Barnett, E. S., Gomez-Pinillos, A., Liu, X., Moore, D., DiPaola, R. & Beer, T. T., Jan 1 2019, In : Clinical Cancer Research. 25, 1, p. 52-63 12 p.

Research output: Contribution to journalArticle

7 Scopus citations

Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer(Figure presented.)

Chen, W. S., Aggarwal, R., Zhang, L., Zhao, S. G., Thomas, G. V., Beer, T. M., Quigley, D. A., Foye, A., Playdle, D., Huang, J., Lloyd, P., Lu, E., Sun, D., Guan, X., Rettig, M., Gleave, M., Evans, C. P., Youngren, J., True, L., Lara, P. & 8 others, Kothari, V., Xia, Z., Chi, K. N., Reiter, R. E., Maher, C. A., Feng, F. Y., Small, E. J. & Alumkal, J. J., Nov 2019, In : European Urology. 76, 5, p. 562-571 10 p.

Research output: Contribution to journalArticle

14 Scopus citations
4 Scopus citations

MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer

Nickols, N. G., Nazarian, R., Zhao, S. G., Tan, V., Uzunangelov, V., Xia, Z., Baertsch, R., Neeman, E., Gao, A. C., Thomas, G. V., Howard, L., De Hoedt, A. M., Stuart, J., Goldstein, T., Chi, K., Gleave, M. E., Graff, J. N., Beer, T. M., Drake, J. M., Evans, C. P. & 11 others, Aggarwal, R., Foye, A., Feng, F. Y., Small, E. J., Aronson, W. J., Freedland, S. J., Witte, O. N., Huang, J., Alumkal, J. J., Reiter, R. E. & Rettig, M. B., Dec 1 2019, In : Prostate Cancer and Prostatic Diseases. 22, 4, p. 531-538 8 p.

Research output: Contribution to journalArticle

Open Access
7 Scopus citations

Prognostic Association of Prostate-specific Antigen Decline with Clinical Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide in a Randomized Clinical Trial

Armstrong, A. J., Lin, P., Higano, C. S., Iversen, P., Sternberg, C. N., Tombal, B., Phung, D., Parli, T., Krivoshik, A. & Beer, T. M., Nov 1 2019, In : European urology oncology. 2, 6, p. 677-684 8 p.

Research output: Contribution to journalArticle

Open Access
3 Scopus citations

Whole-genome and transcriptional analysis of treatment-emergent small-cell neuroendocrine prostate cancer demonstrates intraclass heterogeneity

Aggarwal, R. R., Quigley, D. A., Huang, J., Zhang, L., Beer, T. M., Rettig, M. B., Reiter, R. E., Gleave, M. E., Thomas, G. V., Foye, A., Playdle, D., Lloyd, P., Chi, K. N., Evans, C. P., Lara, P. N., Feng, F. Y., Alumkal, J. J. & Small, E. J., Jun 1 2019, In : Molecular Cancer Research. 17, 6, p. 1235-1240 6 p.

Research output: Contribution to journalArticle

5 Scopus citations
2018

Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: A multi-institutional prospective study

Aggarwal, R., Huang, J., Alumkal, J. J., Zhang, L., Feng, F. Y., Thomas, G. V., Weinstein, A. S., Friedl, V., Zhang, C., Witte, O. N., Lloyd, P., Gleave, M., Evans, C. P., Youngren, J., Beer, T. M., Rettig, M., Wong, C. K., True, L., Foye, A., Playdle, D. & 11 others, Ryan, C. J., Lara, P., Chi, K. N., Uzunangelov, V., Sokolov, A., Newton, Y., Beltran, H., Demichelis, F., Rubin, M. A., Stuart, J. M. & Small, E. J., Aug 20 2018, In : Journal of Clinical Oncology. 36, 24, p. 2492-2503 12 p.

Research output: Contribution to journalArticle

100 Scopus citations

Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer

Armstrong, A. J., Lin, P., Higano, C. S., Sternberg, C. N., Sonpavde, G., Tombal, B., Templeton, A. J., Fizazi, K., Phung, D., Wong, E. K., Krivoshik, A. & Beer, T. M., Jan 1 2018, In : Annals of Oncology. 29, 11, p. 2200-2207 8 p.

Research output: Contribution to journalArticle

11 Scopus citations

DNA repair gene alterations and PARP inhibitor response in patients with metastatic castration-resistant prostate cancer

Lu, E., Thomas, G. V., Chen, Y., Wyatt, A. W., Lloyd, P., Youngren, J., Quigley, D., Bergan, R., Bailey, S., Beer, T. M., Feng, F. Y., Small, E. J. & Alumkal, J. J., Aug 1 2018, In : JNCCN Journal of the National Comprehensive Cancer Network. 16, 8, p. 933-937 5 p.

Research output: Contribution to journalArticle

3 Scopus citations

Evolving intersection between inherited cancer genetics and therapeutic clinical trials in prostate cancer: A white paper from the germline genetics working group of the prostate cancer clinical trials consortium

Carlo, M. I., Giri, V. N., Paller, C. J., Abida, W., Alumkal, J. J., Beer, T. M., Beltran, H., George, D. J., Heath, E. I., Higano, C. S., McKay, R. R., Morgans, A. K., Patnaik, A., Ryan, C. J., Schaeffer, E. M., Stadler, W. M., Taplin, M. E., Kauff, N. D., Vinson, J., S.Antonarakis, E. & 1 others, Cheng, H. H., Jan 1 2018, In : JCO Precision Oncology. 2

Research output: Contribution to journalArticle

8 Scopus citations

Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer

Quigley, D. A., Dang, H. X., Zhao, S. G., Lloyd, P., Aggarwal, R., Alumkal, J. J., Foye, A., Kothari, V., Perry, M. D., Bailey, A. M., Playdle, D., Barnard, T. J., Zhang, L., Zhang, J., Youngren, J. F., Cieslik, M. P., Parolia, A., Beer, T. M., Thomas, G., Chi, K. N. & 43 others, Gleave, M., Lack, N. A., Zoubeidi, A., Reiter, R. E., Rettig, M. B., Witte, O., Ryan, C. J., Fong, L., Kim, W., Friedlander, T., Chou, J., Li, H., Das, R., Li, H., Moussavi-Baygi, R., Goodarzi, H., Gilbert, L. A., Lara, P. N., Evans, C. P., Goldstein, T. C., Stuart, J. M., Tomlins, S. A., Spratt, D. E., Cheetham, R. K., Cheng, D. T., Farh, K., Gehring, J. S., Hakenberg, J., Liao, A., Febbo, P. G., Shon, J., Sickler, B., Batzoglou, S., Knudsen, K. E., He, H. H., Huang, J., Wyatt, A. W., Dehm, S. M., Ashworth, A., Chinnaiyan, A. M., Maher, C. A., Small, E. J. & Feng, F. Y., Jul 26 2018, In : Cell. 174, 3, p. 758-769.e9

Research output: Contribution to journalArticle

97 Scopus citations
7 Scopus citations

Interplay between hypoxia and androgen controls a metabolic switch conferring resistance to androgen/AR-targeted therapy

Geng, H., Xue, C., Mendonca, J., Sun, X. X., Liu, Q., Reardon, P. N., Chen, Y., Qian, K., Hua, V., Chen, A., Pan, F., Yuan, J., Dang, S., Beer, T. M., Dai, M. S., Kachhap, S. K. & Qian, D. Z., Dec 1 2018, In : Nature communications. 9, 1, 4972.

Research output: Contribution to journalArticle

9 Scopus citations

LSD1 activates a lethal prostate cancer gene network independently of its demethylase function

Sehrawat, A., Gao, L., Wang, Y., Bankhead, A., McWeeney, S. K., King, C. J., Schwartzman, J., Urrutia, J., Bisson, W. H., Coleman, D. J., Joshi, S. K., Kim, D. H., Sampson, D. A., Weinmann, S., Kallakury, B. V. S., Berry, D. L., Haque, R., Van Den Eeden, S. K., Sharma, S., Bearss, J. & 4 others, Beer, T. M., Thomas, G. V., Heiser, L. M. & Alumkal, J. J., May 1 2018, In : Proceedings of the National Academy of Sciences of the United States of America. 115, 18, p. E4179-E4188

Research output: Contribution to journalArticle

42 Scopus citations

Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017 [Figure presented]

Gillessen, S., Attard, G., Beer, T. M., Beltran, H., Bossi, A., Bristow, R., Carver, B., Castellano, D., Chung, B. H., Clarke, N., Daugaard, G., Davis, I. D., de Bono, J., Borges dos Reis, R., Drake, C. G., Eeles, R., Efstathiou, E., Evans, C. P., Fanti, S., Feng, F. & 41 others, Fizazi, K., Frydenberg, M., Gleave, M., Halabi, S., Heidenreich, A., Higano, C. S., James, N., Kantoff, P., Kellokumpu-Lehtinen, P. L., Khauli, R. B., Kramer, G., Logothetis, C., Maluf, F., Morgans, A. K., Morris, M. J., Mottet, N., Murthy, V., Oh, W., Ost, P., Padhani, A. R., Parker, C., Pritchard, C. C., Roach, M., Rubin, M. A., Ryan, C., Saad, F., Sartor, O., Scher, H., Sella, A., Shore, N., Smith, M., Soule, H., Sternberg, C. N., Suzuki, H., Sweeney, C., Sydes, M. R., Tannock, I., Tombal, B., Valdagni, R., Wiegel, T. & Omlin, A., Feb 2018, In : European Urology. 73, 2, p. 178-211 34 p.

Research output: Contribution to journalArticle

228 Scopus citations

Radiographic progression-free survival as a clinically meaningful end point in metastatic castration-resistant prostate cancer: The PREVAIL randomized clinical trial

Rathkopf, D. E., Beer, T. T., Loriot, Y., Higano, C. S., Armstrong, A. J., Sternberg, C. N., De Bono, J. S., Tombal, B., Parli, T., Bhattacharya, S., Phung, D., Krivoshik, A., Scher, H. I. & Morris, M. J., May 1 2018, In : JAMA oncology. 4, 5, p. 694-701 8 p.

Research output: Contribution to journalArticle

13 Scopus citations
2017

Analysis of circulating cell-free DnA identifies multiclonal heterogeneity of BRCA2 reversion mutations associated with resistance to PARP inhibitors

Quigley, D., Alumkal, J. J., Wyatt, A. W., Kothari, V., Foye, A., Lloyd, P., Aggarwal, R., Kim, W., Lu, E., Schwartzman, J., Beja, K., Annala, M., Das, R., Diolaiti, M., Pritchard, C., Thomas, G., Tomlins, S., Knudsen, K., Lord, C. J., Ryan, C. & 5 others, Youngren, J., Beer, T. M., Ashworth, A., Small, E. J. & Feng, F. Y., Sep 2017, In : Cancer discovery. 7, 9, p. 999-1005 7 p.

Research output: Contribution to journalArticle

84 Scopus citations

Clinical Outcomes of Chemotherapy Naïve Men with Metastatic Castration Resistant Prostate Cancer and Low Baseline Prostate Specific Antigen Treated with Enzalutamide vs Placebo

Taplin, M. E., Armstrong, A. J., Lin, P., Krivoshik, A., Phung, D., Parli, T., Tombal, B. & Beer, T. T., 2017, (Accepted/In press) In : Journal of Urology.

Research output: Contribution to journalArticle

6 Scopus citations

Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer

Wyatt, A. W., Annala, M., Aggarwal, R., Beja, K., Feng, F., Youngren, J., Foye, A., Lloyd, P., Nykter, M., Beer, T. M., Alumkal, J. J., Thomas, G. V., Reiter, R. E., Rettig, M. B., Evans, C. P., Gao, A. C., Chi, K. N., Small, E. J. & Gleave, M. E., Dec 1 2017, In : Journal of the National Cancer Institute. 109, 12

Research output: Contribution to journalArticle

86 Scopus citations

CT–Guided Bone Biopsies in Metastatic Castration-Resistant Prostate Cancer: Factors Predictive of Maximum Tumor Yield

Holmes, M. G., Foss, E., Joseph, G., Foye, A., Beckett, B., Motamedi, D., Youngren, J., Thomas, G. V., Huang, J., Aggarwal, R., Alumkal, J. J., Beer, T. M., Small, E. J. & Link, T. M., Aug 2017, In : Journal of Vascular and Interventional Radiology. 28, 8, p. 1073-1081.e1

Research output: Contribution to journalArticle

15 Scopus citations

Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial

Beer, T. M., Hotte, S. J., Saad, F., Alekseev, B., Matveev, V., Fléchon, A., Gravis, G., Joly, F., Chi, K. N., Malik, Z., Blumenstein, B., Stewart, P. S., Jacobs, C. A. & Fizazi, K., Nov 2017, In : The Lancet Oncology. 18, 11, p. 1532-1542 11 p.

Research output: Contribution to journalArticle

31 Scopus citations

Cyclooxygenase-2 (COX-2) inhibition for prostate cancer chemoprevention: double-blind randomised study of pre-prostatectomy celecoxib or placebo

Flamiatos, J. F., Beer, T. M., Graff, J. N., Eilers, K. M., Tian, W., Sekhon, H. S. & Garzotto, M., May 1 2017, In : BJU international. 119, 5, p. 709-716 8 p.

Research output: Contribution to journalArticle

13 Scopus citations

Docetaxel and mitoxantrone before radical prostatectomy in men with high-risk prostate cancer: 10-year follow-up and immune correlates

Bergstrom, C. P., Ruffell, B., Ho, C. M. T., Higano, C. S., Ellis, W. J., Garzotto, M., Beer, T. M. & Graff, J. N., Jan 2017, In : Anti-Cancer Drugs. 28, 1, p. 120-126 7 p.

Research output: Contribution to journalArticle

9 Scopus citations

Effect of Visceral Disease Site on Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide in the PREVAIL Trial

Alumkal, J. J., Chowdhury, S., Loriot, Y., Sternberg, C. N., de Bono, J. S., Tombal, B., Carles, J., Flaig, T. W., Dorff, T. B., Phung, D., Forer, D., Noonberg, S. B., Mansbach, H., Beer, T. M. & Higano, C. S., Oct 2017, In : Clinical Genitourinary Cancer. 15, 5, p. 610-617.e3

Research output: Contribution to journalArticle

7 Scopus citations
17 Scopus citations

Health-related quality of life effects of enzalutamide in patients with metastatic castration-resistant prostate cancer: An in-depth post hoc analysis of EQ-5D data from the PREVAIL trial

Devlin, N., Herdman, M., Pavesi, M., Phung, D., Naidoo, S., Beer, T. M., Tombal, B., Loriot, Y., Ivanescu, C., Parli, T., Balk, M. & Holmstrom, S., Jun 23 2017, In : Health and Quality of Life Outcomes. 15, 1, 130.

Research output: Contribution to journalArticle

8 Scopus citations

High-Dose Abiraterone Acetate in Men With Castration Resistant Prostate Cancer

Friedlander, T. W., Graff, J. N., Zejnullahu, K., Anantharaman, A., Zhang, L., Paz, R., Premasekharan, G., Russell, C., Huang, Y., Kim, W., Aggarwal, R. R., Lin, A. M., Fong, L., Alumkal, J. J., Beer, T. M., Sharifi, N., Alyamani, M., Dittamore, R., Small, E. J., Paris, P. L. & 1 others, Ryan, C. J., Dec 2017, In : Clinical Genitourinary Cancer. 15, 6, p. 733-741.e1

Research output: Contribution to journalArticle

8 Scopus citations

Management of castration-resistant, taxane-resistant prostate cancer

Beer, T. T., Aug 15 2017, In : ONCOLOGY (United States). 31, 8, p. 1-5 5 p.

Research output: Contribution to journalArticle

Management of Castration-Resistant, Taxane-Resistant Prostate Cancer

Beer, T. M., Aug 15 2017, In : Oncology (Williston Park, N.Y.). 31, 8, p. 633-636 4 p.

Research output: Contribution to journalArticle

2 Scopus citations

Molecular testing in patients with castration-resistant prostate cancer and its impact on clinical decision making

Tao, D. L., Bailey, S., Beer, T. M., Foss, E., Beckett, B., Fung, A., Foster, B. R., Guimaraes, A., Cetnar, J. P., Graff, J. N., Eilers, K. M., Small, E. J., Corless, C. L., Thomas, G. & Alumkal, J. J., 2017, In : JCO Precision Oncology. 2017, 1, p. 1-11 11 p.

Research output: Contribution to journalArticle

5 Scopus citations

Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer

Armstrong, A. J., Halabi, S., Healy, P., Alumkal, J., Winters, C., Kephart, J., Bitting, R. L., Hobbs, C., Soleau, C. F., Beer, T. T., Slottke, R., Mundy, K., Yu, E. Y. & George, D. J., Aug 1 2017, In : European Journal of Cancer. 81, p. 228-236 9 p.

Research output: Contribution to journalArticle

31 Scopus citations

Post hoc analyses of East Asian patients from the randomized placebo-controlled PREVAIL trial of enzalutamide in patients with chemotherapy-naïve, metastatic castration-resistant prostate cancer

Kim, C. S., Choi, Y. D., Lee, S. E., Lee, H. M., Ueda, T., Yonese, J., Fukagai, T., Chiong, E., Lau, W., Abhyankar, S., Theeuwes, A., Tombal, B., Beer, T. M. & Kimura, G., Jul 1 2017, In : Medicine (United States). 96, 27, e7223.

Research output: Contribution to journalArticle

7 Scopus citations

Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: Post hoc analysis of PREVAIL

Bryce, A. H., Alumkal, J. J., Armstrong, A., Higano, C. S., Iversen, P., Sternberg, C. N., Rathkopf, D., Loriot, Y., De Bono, J., Tombal, B., Abhyankar, S., Lin, P., Krivoshik, A., Phung, D. & Beer, T. M., Jun 1 2017, In : Prostate Cancer and Prostatic Diseases. 20, 2, p. 221-227 7 p.

Research output: Contribution to journalArticle

19 Scopus citations

Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer

Beer, T. T., Kwon, E. D., Drake, C. G., Fizazi, K., Logothetis, C., Gravis, G., Ganju, V., Polikoff, J., Saad, F., Humanski, P., Piulats, J. M., Mella, P. G., Ng, S. S., Jaeger, D., Parnis, F. X., Franke, F. A., Puente, J., Carvajal, R., Sengeløv, L., McHenry, M. B. & 3 others, Varma, A., Van Den Eertwegh, A. J. & Gerritsen, W., Jan 1 2017, In : Journal of Clinical Oncology. 35, 1, p. 40-47 8 p.

Research output: Contribution to journalArticle

211 Scopus citations

Should Chemotherapy Be Used in Nonmetastatic Prostate Cancer?

Graff, J., Alumkal, J. & Beer, T. T., Jan 1 2017, In : JAMA oncology. 3, 1, p. 11-12 2 p.

Research output: Contribution to journalArticle

3 Scopus citations

Skeletal-related events significantly impact health-related quality of life in metastatic castration-resistant prostate cancer: Data from PREVAIL and AFFIRM trials

Saad, F., Ivanescu, C., Phung, D., Loriot, Y., Abhyankar, S., Beer, T. T., Tombal, B. & Holmstrom, S., Mar 1 2017, In : Prostate Cancer and Prostatic Diseases. 20, 1, p. 110-116 7 p.

Research output: Contribution to journalArticle

19 Scopus citations

Taking Care of Our Friends and Neighbors: DeVita's The Death of Cancer and the Challenge of Letting Go

Beer, T. T. & Prasad, V., Jan 1 2017, In : JAMA oncology. 3, 1, p. 16-17 2 p.

Research output: Contribution to journalArticle

3 Scopus citations

The association between health-related quality-of-life scores and clinical outcomes in metastatic castration-resistant prostate cancer patients: Exploratory analyses of AFFIRM and PREVAIL studies

Beer, T. T., Miller, K., Tombal, B., Cella, D., Phung, D., Holmstrom, S., Ivanescu, C., Skaltsa, K. & Naidoo, S., Dec 1 2017, In : European Journal of Cancer. 87, p. 21-29 9 p.

Research output: Contribution to journalArticle

11 Scopus citations
2016
37 Scopus citations

Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor

Coleman, D. J., Van Hook, K., King, C. J., Schwartzman, J., Lisac, R., Urrutia, J., Sehrawat, A., Woodward, J., Wang, N. J., Gulati, R., Thomas, G. V., Beer, T. M., Gleave, M., Korkola, J. E., Gao, L., Heiser, L. M. & Alumkal, J. J., 2016, In : Oncotarget. 7, 26, p. 40690 1 p.

Research output: Contribution to journalArticle

Open Access
7 Scopus citations

Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer

Graff, J. N., Alumkal, J. J., Drake, C. G., Thomas, G. V., Redmond, W. L., Farhad, M., Cetnar, J. P., Ey, F. S., Bergan, R. C., Slottke, R. & Beer, T. M., Aug 1 2016, In : Oncotarget. 7, 33, p. 52810-52817 8 p.

Research output: Contribution to journalArticle

175 Scopus citations

Effects of ω-3 Fatty Acids and Catechins on Fatty Acid Synthase in the Prostate: A Randomized Controlled Trial

Zhang, Z., Garzotto, M., Beer, T. M., Thuillier, P., Lieberman, S., Mori, M., Stoller, W. A., Farris, P. E. & Shannon, J., Nov 16 2016, In : Nutrition and Cancer. 68, 8, p. 1309-1319 11 p.

Research output: Contribution to journalArticle

5 Scopus citations

Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castrationresistant prostate cancer: Results from PREVAIL

Graff, J. N., Baciarello, G., Armstrong, A. J., Higano, C. S., Iversen, P., Flaig, T. W., Forer, D., Parli, T., Phung, D., Tombal, B., Beer, T. M. & Sternberg, C. N., Feb 1 2016, In : Annals of Oncology. 27, 2, p. 286-294 9 p.

Research output: Contribution to journalArticle

47 Scopus citations

Enzalutamide in Japanese patients with chemotherapy-naïve, metastatic castration-resistant prostate cancer: A post-hoc analysis of the placebo-controlled PREVAIL trial

Kimura, G., Yonese, J., Fukagai, T., Kamba, T., Nishimura, K., Nozawa, M., Mansbach, H., Theeuwes, A., Beer, T. M., Tombal, B. & Ueda, T., May 1 2016, In : International Journal of Urology. 23, 5, p. 395-403 9 p.

Research output: Contribution to journalArticle

13 Scopus citations